Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Benevolent AI CEO discusses 2023 highlights and 2024 outlook as it pioneers AI in drug discovery

BenevolentAI

BenevolentAI (OTC:BAIVF) CEO Dr Joerg Moeller outlines the company's operational and corporate milestones for 2023, categorising achievements into five key areas: clinic operations, proprietary pipeline progress, platform enhancement, organisational growth, and financial management. Moeller noted that BAI secured a significant deal with Merck KGaA worth up to $594 million for developing three clinical drug candidates in immunology and oncology. Collaborations with AstraZeneca have also advanced, focusing on target selection for diseases such as systemic lupus. Progress was noted in Benevolent AI's proprietary pipeline, especially with a lead asset in ulcerative colitis expected to deliver Phase 1a study data. Additionally, advancements in glioblastoma treatment and ALS research were highlighted. Organisational developments included key executive appointments and an extended financial runway until mid-next year. Moeller underscored the validation of the BAI platform through collaborations with the major pharmaceutical companies, positioning the company as a leader in AI-augmented drug discovery. The imminent release of data for a leading program in ulcerative colitis aims to introduce a new treatment with fewer side effects. For 2024, the company plans to extend its financial runway, forge additional collaborations, and partner on pipeline assets, with expectations for another year of significant achievements. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 21, 2024 11:50 AM Eastern Daylight Time

Video

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application, marking a significant step in the company's intellectual property (IP) strategy. This latest patent is distinct from two others granted last year, focusing on the composition of matter protecting a specific polymorph of vidofludimus calcium. The company aims to ensure broad protection and exclusivity for vidofludimus calcium, especially as it approaches the final development stage. Vitt highlighted Immunic's global patent strategy, aiming to cover all important territories and build multiple protection layers around their inventions. The strategy includes securing patents not only for the medical use of their discoveries but also for the materials themselves. The newly allowed patent extends until 2039, with potential for extension. For the use of vidofludimus calcium in MS, Vitt estimates exclusivity extending into 2041, Vitt estimates exclusivity extending into 2041, ensuring a significant period for exclusive marketing in major markets, particularly the US. Immunic now has eight families of patents in the US, with three major patents granted or allowed in the past three months, significantly enhancing their IP portfolio for vidofludimus calcium. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 21, 2024 11:37 AM Eastern Daylight Time

Video

Quantum Pathology Enhances Digital Pathology Capabilities with the Adoption of PathAI's AISight Image Management System

PathAI

Quantum Pathology, LLC, an independent pathology service provider in the United States, today announced the adoption of the AISight[i] Image Management System, a leading end-to-end workflow and image management solution by PathAI. This strategic decision marks a significant step forward in Quantum Pathology's transition to digital pathology, leveraging the advanced capabilities of AISight to revolutionize its operations. In a rapidly evolving landscape where competition for pathologists and pathology services is intensifying, the integration of digital pathology and artificial intelligence emerges as a crucial differentiator for players in the independent pathology market. After evaluating several image management systems, Quantum Pathology identified the AISight Image Management System as the most compelling solution to streamline its workflow, enhance case prioritization, and facilitate TC/PC use cases. By embracing AISight, Quantum Pathology aims not only to expedite turnaround times for referring physicians but also to harness AI overlays for delivering next-generation insights on patient pathology. "As the demand for pathology services grows, embracing digital pathology and AI-driven solutions becomes imperative for staying ahead. AISight emerged as the frontrunner among image management systems, offering the versatility and robustness needed to manage our caseload effectively as well as the full menu of algorithms we require to drive efficiencies in our workflow both in-house and amongst our professional clients,” said Dr. May Azar, Chief Medical Officer and Medical Director of Quantum Pathology. AISight, a cloud-native intelligent enterprise workflow solution, stands as a cornerstone in the digital pathology ecosystem, trusted by hundreds of pathologists worldwide. Serving as a centralized platform for case management, workload balancing, and image management, AISight integrates best-in-class artificial intelligence tools from PathAI and third-party partners. This comprehensive approach enables Quantum Pathology to address a wide spectrum of histopathology use cases with efficiency and precision. "The adoption of digital pathology represents a pivotal moment in healthcare, and we are witnessing a surge in laboratories embracing innovative image management systems. AISight stands out as a versatile solution that not only delivers high-quality images promptly but also empowers pathologists with a suite of AI algorithms for unparalleled workflow efficiency,” said Eric Walk, MD, FCAP, Chief Medical Officer of PathAI. “We are thrilled to partner with Quantum Pathology and support their journey towards digital transformation." [i] AISight is For Research Use Only. Not for use in diagnostic procedures. About Quantum Pathology Quantum Pathology is an independent, nationally renowned, fully accredited pathology laboratory committed to providing the best in class in patient care, latest technology, turnaround time and customer service. Quantum’s highly trained team of medical professionals and client relations specialists provide fast, accurate, personalized laboratory services, as well as a full range of ancillary support and practice management solutions. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAI’s digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. ### Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

March 21, 2024 10:00 AM Eastern Daylight Time

National Contract Management Association Announces New Board of Directors

National Contract Management Association

The National Contract Management Association (NCMA), dedicated to the advancement and expansion of the contract management profession, announced today the appointment of its new Board of Directors. The program year 2025 new Directors include David Bassett and Manuel Mendez; reappointed are Joy White, and Cameron Holt as Wendy Masiello and Heidi Timmerman transition from the Board. All bring a wealth of experience and expertise in contract management which will further strengthen the association’s strategic direction, transformation, and growth. "As we further our mission to advance the contract management profession and fortify its ties with other acquisition-related communities through advocacy, standards, and professional development, the addition of these individuals is significant,” said Board Chair-Elect, Heather Gerczak. “Their collective wealth of experience, knowledge, and leadership promises to invigorate our organization, propelling us closer to our goals. We eagerly anticipate their contributions as we chart our course forward." Lieutenant General David Bassett (US Army Retired), Founder of Acquisition Insight LLC, provides business consulting to firms aiming to work with the federal government for superior technology access. With over 35 years in the Army, serving as Army Program Executive Officer Ground Combat Systems, Program Executive Officer Command Control Communications Tactical, and Deputy Program Executive Officer for Combat Support and Combat Service Support, and retiring as Director of Defense Contract Management Agency, he managed 250,000 contracts worth $3.5T. Mr. Bassett holds Master’s Degrees in National Resource Strategy and Computer Science, and a Bachelor’s Degree in Electrical Engineering from the University of Virginia. As Integral Federal's Chief Financial Officer, Manuel Mendez leads business operations, supporting strategic direction and growth. He manages financial planning, reporting, compliance, mergers, acquisitions, auditing, program finance, contracts, IT, quality, and pricing. Previously, he served as VP of Financial Planning and Analysis at PAE, facilitating its divestiture, IPO, acquisitions, and sale to private equity. With senior financial roles at Engility and Harris Corporation, Mendez brings extensive experience. He holds a B.S. in Industrial Engineering from Universidad de Los Andes and an M.B.A. from Georgetown University. Joy White, Executive Director at Space Systems Command (SSC) has been reappointed to the Board. Ms. White oversees a $15B annual portfolio of major acquisition space programs, ensuring agile, integrated, and resilient capabilities for national defense. She leads SSC's business operations, talent management, and acquisition functional expertise for the United States Space Force, overseeing a workforce of 15,000 personnel at 29 operating locations. Ms. White started her federal service as a contracting intern at SSC and has a diverse background including legal analysis and advisory roles at the Office of the Assistant Secretary of the Air Force for Acquisition. Also reappointed, Major General Cameron Holt (US AF Retired), President at Exiger Government Solutions. Mr. Holt formerly served as Deputy Assistant Secretary for Contracting, Office of the Assistant Secretary of the Air Force for Acquisition, Technology, and Logistics. Leading a team managing $825B in programs, he focused on Space, Global Power/Reach, and Information Dominance. He also supervised the training, organization, and equipping of 8,000 Contracting professionals handling over $65B in programs annually. Receiving his commission from the University of Georgia in 1990, Mr. Holt has extensive experience in acquisition and contract management across major commands and deployments supporting Operation Enduring Freedom. "It has been an honor to work with Wendy Masiello and Heidi Timmerman for their support and guidance over their two terms. They have been instrumental in navigating NCMA through a period of growth and change," said NCMA Chief Executive Officer, Kraig Conrad. "I am pleased to welcome in our new Board Members, their impressive experience will be invaluable to help grow our Common Language, certifications, and professional development avenues for our community." The NCMA Board of Directors is responsible for setting the strategic direction of the organization, ensuring its financial stability, and overseeing the development and delivery of member services and educational programs. The NCMA Contract Management Standard™ (CMS™) is an important program for the Board as the ANSI-approved standard covers the many practices within the contract management life cycle, including procurement and purchasing. Board members serve three-year terms. Beginning July 2024, the newly appointed Board will officially assume their duties and convene at NCMA's World Congress conference in Seattle, WA. The National Contract Management Association (NCMA) – www.ncmahq.org – has grown as a professional society whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. Contact Details National Contract Management Association Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

March 21, 2024 05:00 AM Eastern Daylight Time

Image

YourFMO Reaches a Donation Milestone: Equivalent of 10 Million Meals Donated to Feeding America®

YourFMO

YourFMO, a national, non-governmental, independent marketing organization that provides agents with valuable resources they need to help clients decide on Medicare options, announced that it has reached a major milestone in its partnership with Feeding America ®: YourFMO has donated in excess of 10 million meals since 2019. Since starting its partnership with Feeding America, YourFMO has donated the equivalent of 10 meals* for every effective insurance enrollment that agents submit through the YourFMO Enrollment Center. “When we started our partnership with Feeding America, the idea of donating the equivalent of 1 million meals seemed like an ambitious goal,” said Matthew Graham, senior vice president and YourFMO program leader. “The independent agents who embrace our enrollment center in Q4 of 2023 fueled us to surpass this 10-million-meal milestone.” YourFMO and Feeding America share a common goal to support America’s senior population. According to Feeding America, 5.5 million seniors (1 in 14 or 7.1%), age 60 and older, were food insecure in 2021. Every state is home to seniors and older adults who experience food insecurity. Feeding America is committed to an America where no one is hungry. The organization partners with people experiencing food insecurity, policymakers, organizations and supporters, united with them in a movement to end hunger. “We are so grateful for partners like YourFMO, whose commitment to Feeding America has resulted in a remarkable milestone of 10 million meals donated since 2019,” said Lauren Biedron, Feeding America’s Senior Vice President of Corporate Partnerships. “Their dedication has had a far-reaching impact on local food banks and their surrounding communities in addressing hunger, including the critical issue of senior hunger.” YourFMO’s closest business partners appreciate the opportunity to support Feeding America when they use the enrollment center. “Many of the companies in the AmeriLife portfolio rely on YourFMO’s platform to efficiently process Medicare enrollments,” said Scotty Elliott, Chief Distribution Officer of Health at AmeriLife. “The ability to also play a role in helping to feed seniors who are battling food insecurities is a benefit that can’t be overstated.” YourFMO’s efforts to support Feeding America have also helped inspire AmeriLife’s corporate giving efforts. During last year’s Valspar Championship, AmeriLife – in partnership with local affiliate Feeding Tampa Bay – sponsored a food donation drive at the golf tournament. Fans eagerly responded by donating 5,000 pounds of shelf-stable food items, and the two partners look forward to hosting this food drive activation once again during the final round of the 2024 Valspar Championship on Sunday, March 24. “YourFMO helped introduce us to the worthwhile efforts of Feeding America,” said Elliott. “We’re proud to hold another donation drive at this year’s tournament and help those in our community who are facing hunger.” YourFMO sees its partnership with Feeding America as an ongoing commitment. “I know I can speak for the entire YourFMO team in saying we’re incredibly grateful for the support from our independent agents who helped us reach 10 million donated meals,” added Graham. “I’m excited to see how many more meals we can donate and how many neighbors in need we can support in 2024 and in years to come.” Individuals who want to support YourFMO’s efforts can visit its Team Feed Corporate donation page to make a financial contribution. *$1 helps provide at least 10 meals ### About YourFMO YourFMO is a national non-government, independent marketing organization that is a one-stop shop for independent agents to grow their business. The site provides agents with the information they need to help their clients make thoughtful Medicare decisions. YourFMO provides agent and consumer resources, including the YourFMO Enrollment Center, which is a multi-carrier platform that allows agents to compare, quote, and enroll their clients conveniently in one place. For more information, visit YourFMO.com. About Feeding America Feeding America is committed to an America where no one is hungry. We support tens of millions of people who experience food insecurity to get the food and resources they say they need to thrive as part of a nationwide network of food banks, statewide food bank associations, food pantries and meal programs. We also invest in innovative solutions to increase equitable access to nutritious food, advocate for legislation that improves food security and work to address factors that impact food security, such as health, cost of living and employment. We partner with people experiencing food insecurity, policymakers, organizations, and supporters, united with them in a movement to end hunger. Visit FeedingAmerica.org to learn more. Contact Details AmeriLife for YourFMO Jeff Maldonado media@amerilife.com Company Website https://yourfmo.com/

March 20, 2024 01:00 PM Eastern Daylight Time

ASSOCIATION OF PICKLEBALL PLAYERS, UTR SPORTS LAUNCH FUNDRAISING PROGRAM TO SUPPORT AMERICAN CANCER SOCIETY THROUGH PICKLEBALL

AOPP

The Association of Pickleball Players (APP), the American Cancer Society and UTR Sports are teaming up to fight cancer through Doubles Dink for Cancer, a first-of-its-kind community-based fundraising program. The year-round program is designed to unite communities around the beloved sport of pickleball and in support of a single mission: to end cancer as we know it, for everyone. With nearly 50 million adult Americans playing pickleball, Doubles Dink for Cancer invites players of all levels to play pickleball or organize an event to celebrate cancer survivors, remember loved ones lost to cancer and raise funds to improve the lives of people with cancer and their families. Hosted on UTR Sports’ innovative software, these volunteer-led, round robin doubles tournaments can happen anytime, anywhere—from a local pickleball or tennis club, to community courts or even homemade, temporary courts lined with chalk. Events are designed to be fun and open to everyone, including the most experienced pickleball players and people picking up a paddle for the first time. “Pickleball offers physical, social and emotional benefits—all important to a battle against cancer. Doubles Dink for Cancer builds on this as a fun way to get moving, raise awareness and leverage the pickleball community for good,” said APP Founder Ken Herrmann. “With the majority of people having a personal connection to cancer, we hope you join us in rallying behind the American Cancer Society to bring renewed hope for patients and their families on a national scale.” Doubles Dink for Cancer will also showcase how pickleball can play a part in cancer avoidance, as people maintain an active and healthy lifestyle—an important factor in reducing cancer risk. Cancer can impact anyone at any age and finding cancer early increases survival rates. According to the American Cancer Society, more than 1.9 million people are expected to be diagnosed with cancer this year. At present, one in two men and one in three women in the United States will receive a cancer diagnosis in their lifetime. Doubles Dink for Cancer will donate 70 percent of proceeds from registration fees to further the American Cancer Society’s mission through funding cancer research discoveries, enhancing direct patient support in 20,000 communities across the country and through advocating for policies that enhance access to cancer care. “We’re excited to work with the Association of Pickleball Players to broaden our reach and amplify the message that physical activity, like playing pickleball, can help prevent cancer,” said Dr. Arif Kamal, chief patient officer at the American Cancer Society. “Uniting this community around reducing cancer risks and supporting our mission is invaluable and will help us impact more lives.” Doubles Dink for Cancer is now live in Florida, providing a pilot launch in one of the strongest pickleball communities in the world before its national roll out in Summer 2024. The Miami-Fort Lauderdale metropolitan area represents the single largest concentration of pickleball players in Florida, with 20 percent of the state’s pickleball-playing population residing in the area. According to the APP’s 2023 player participation research data, the Miami-Fort Lauderdale metropolitan area is the fourth largest pickleball market in the nation, with 3.1 percent of their population having played the sport at least once in the past twelve months. Each Doubles Dink for Cancer event, regardless of tournament size, will be supported with the following signature elements: An event page on UTR Sports where organizers can invite friends, manage registration and communicate with players Resources for beginner event organizers to easily manage the tournament, including a toolkit with sample schedules, scoresheets, brackets, volunteer needs and more For more experienced organizers, access to UTR Sports technology to run the event using its tournament management software Branded T-shirts for event participants “We are excited and honored to be partners on this great initiative,” said Mark Leschly, UTR Sports Chairman and CEO. “Cancer impacts so many Americans, and the opportunity to support the battle while playing the great sport of pickleball is a win for everyone. We are proud to host these events on UTR Sports and look forward to what we can accomplish together.” Community members interested in planning a local event or serving as a Doubles Dink for Cancer ambassador can access resources and additional information at theapp.global/doublesdinkforcancer. Each player will pay a registration fee to participate, as they do for any local tournament or court rental, with 70 percent of proceeds supporting the American Cancer Society’s lifesaving cancer research and commitment to advancing health equity through essential programs and services. In addition to nationwide community events, Doubles Dink for Cancer will have a strong presence at all APP Tour events. Local cancer survivors, caregivers, advocates and their families will be recognized on Championship Court for as living proof of the American Cancer Society’s mission. Doubles Dink for Cancer will also be highlighted through on-site activations, signage and broadcasts at APP Tour events. More information, including updates for Doubles Dink for Cancer’s national roll out, will be available at theapp.global/doublesdinkforcancer or by following the APP on Instagram, X, Threads, TikTok, Facebook and LinkedIn. # # # About the APP: The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be seen on internationally televised broadcasts. The APP was founded in 2019 and operates the first and only tour fully and officially sanctioned by USA Pickleball. In 2023, it held 19 events across the country and supported five international tournaments. The APP prides itself on developing the next generation of pickleball champions through its APP Next Gen Series, the APP Next Gen National Team and other youth initiatives. The 2024 schedule, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. About UTR Sports: The mission of UTR Sports (formerly Universal Tennis) is to connect and grow the sports of tennis and pickleball with accurate global ratings, innovative events and a global community centered around level-based play. The UTR Sports Platform is anchored by our patented ratings technology. UTR Sports provides the technology tools and solutions relevant and valuable to players, coaches and organizers. UTR Sports is creating opportunities and pathways, for players from all over the world, in all stages of life, to find better matches and unlock a more fun, affordable and flexible experience. Follow UTR Sports on social media @UTR_Sports. Media Contacts: Julianne Olivo for the APP at jolivo@intersport.global Darrya Lipscomb for the American Cancer Society at darrya.lipscomb@cancer.org The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be seen on internationally televised broadcasts. The APP was founded in 2019 and operates the first and only tour fully and officially sanctioned by USA Pickleball. In 2023, it held 19 events across the country and supported five international tournaments. The APP prides itself on developing the next generation of pickleball champions through its APP Next Gen Series, the APP Next Gen National Team and other youth initiatives. The 2024 schedule, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. Contact Details Julianne Olivo jolivo@intersport.global Company Website https://theapp.global

March 20, 2024 11:00 AM Eastern Daylight Time

Ultrahuman Raises $35mn to accelerate growth and research in the health monitoring space

Ultrahuman

The pioneer in wearable tech Ultrahuman has today announced a $35 million equity and debt investment round. The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space. "This funding round marks a pivotal step forward in our journey to dominate the smart rings space, bringing us closer to our goal of being the market leader" remarked Mohit Kumar, co-founder of Ultrahuman. Ultrahuman is at the forefront of the health-tech revolution, boasting the world's largest and only multi-device health ecosystem. In addition to their smart ring called Ring Air, the Ultrahuman product suite includes a continuous glucose monitoring wearable called M1 Live, a home health device called Ultrahuman Home and a preventive blood testing product called Blood Vision. Their platform integrates glucose, sleep, movement, blood markers, and HRV, offering a comprehensive approach to health monitoring. "The future of health is integrated, and at Ultrahuman, we're making that future a reality today by seamlessly combining various health data streams to empower preventative health and wellness," said Mohit Kumar. Ultrahuman has seen phenomenal growth over the past 12 months, becoming the second-largest player in the smart ring market while maintaining profitability. "Our vision of being the top player in terms of both active devices and geographic presence is within reach, thanks to our rapid expansion and the love we've received from our users," added Mohit Kumar. A key driver of Ultrahuman's explosive growth has been its expansion into over 150 retail outlets worldwide, including iconic locations like London’s Selfridges on Oxford Street, Changi airport in Singapore, and the Virgin megastore in Dubai. This retail footprint expansion has been instrumental in introducing Ultrahuman's cutting-edge technology to a global audience. "Our growth is a testament to the user love for our products, highlighted by industry-leading NPS and engagement metrics since the launch of our latest model, the Ring Air. Our relentless focus on improving user experience through continuous firmware and software updates is what sets us apart," Mohit Kumar emphasized. "Shipping a new firmware version every 2 weeks and weekly app improvements reflect our commitment to excellence and our speed of execution, our biggest competitive advantage. We’ve also iterated in hardware at the speed of software by designing novel devices like Ultrahuman Home, a home health monitor.” Looking ahead, Ultrahuman is on track to surpass $100 million in annualized revenue run rate (ARR) by the end of 2024, a milestone that will be achieved profitably. "Our ability to make long-term manufacturing investments, supported by our profitability, is unique in the smart rings market," Mohit Kumar noted. UltraFactory, a recent addition of a new manufacturing facility, is capable of supporting $200 million in annual revenue, a clear indication of Ultrahuman’s readiness for its next phase of growth. Ultrahuman's dedication to scientific validation and innovation is further evidenced by the completion of a clinical trial involving 105 participants, aimed at validating the ‘Metabolic Score’ generated on the Ultrahuman platform. "Our long-term investment in R&D and intellectual property is a cornerstone of our strategy, ensuring that our products not only meet but exceed the highest standards of efficacy and reliability," Mohit Kumar concluded. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. Ultrahuman’s products include the Ultrahuman M1(continuous glucose monitoring sensor), the Ultrahuman Ring and Blood Vision, a preventive blood testing platform with the pioneering UltraTrace™ technology. By collating different biomarkers, Ultrahuman is helping people improve their energy levels and lifestyle, track their workout, sleep and recovery, and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Ultrahuman was started by Mohit Kumar and Vatsal Singhal, who were also co-founders at Runnr, which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist and a Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). During his training, he observed athletes train smartly via the usage of data, recovery tools and protocols. About Nexus Venture Partners Nexus Venture Partners is a prominent venture capital firm specializing in early-stage investments. They focus on technology-driven startups across various sectors. With a successful track record, Nexus has supported numerous innovative companies in their growth journey. About Blume Ventures Blume Ventures is an India-based venture capital firm known for its strategic investments in early-stage startups. Their portfolio spans diverse domains, including technology, healthcare, and consumer products. Blume’s hands-on approach and mentorship have contributed to the success of several emerging companies. About Steadview Capital Steadview Capital is an investment firm that primarily targets late-stage and growth-stage companies. Their global portfolio includes disruptive startups across industries. Steadview’s investment philosophy emphasizes long-term value creation and sustainable growth. About Deepinder Goyal Deepinder Goyal is the Founder and CEO of Zomato, a leading food delivery and restaurant discovery platform. Under his leadership, Zomato has expanded globally, revolutionizing the way people explore and enjoy dining experiences. His entrepreneurial spirit and commitment to innovation continue to drive Zomato’s success. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.ultrahuman.com/

March 20, 2024 08:00 AM Eastern Daylight Time

Image

News Release

American Aires Inc. (CSE:WIFI; OTC Pink:AAIRF) Proprietary Solution Against EMF Radiation Could Unlock Significant Shareholder Value

AAIRF, EDR, TKO

As the world gets more technologically advanced, there has been a dramatic rise in the number of electronic devices emitting electromagnetic fields (EMFs). EMFs are invisible energy areas associated with electrical power use, and while these EMFs have helped make our lives more convenient and connected, they have also had some unintended consequences. A number of scientific studies have shown that exposure to EMF radiation can trigger inflammation in the brain, which can lead to tissue damage and contribute to the development of various diseases, including neurodegenerative diseases. The results further demonstrated that there was a significant correlation between brain electrical activity and cognitive function, particularly in the areas of attention and working memory. Basically, using devices like your cell phone for just 30 minutes a day can increase brain tumor risks by 40%, while 24 hours of EMF exposure can induce more DNA damage than 1,600 chest x-rays. That is exactly why the Canadian-based nanotechnology company American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF), which is focused on enhancing well-being and environmental safety, has come up with what is possibly the perfect solution to this problem. American Aires has developed a proprietary silicon-based resonator that protects against the harmful effects of electromagnetic radiation. According to the company, its main goal was to find a way to minimize harm to the body without impacting the capability of electronic devices, which meant that the obvious solution was to modulate, rather than block or absorb radiation, to create a surrounding area free from the harm of EMF. So far, the company has dedicated over 20 years and poured at least $20 million into developing its proprietary nanotechnology, which has resulted in sleek and stylish, convenient devices that can be used for both personal and area protection without any need for a power source. Aires' Lifetune products target EMR emitted by consumer electronic devices such as cellphones, computers, baby monitors, and Wi-Fi, including the more powerful and rapidly expanding high-speed 5G networks. More importantly, the effectiveness of the American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) microchip in reducing the harmful effects of EMF radiation has been reaffirmed by the scientific community. A recently published study in the Link Journal confirmed the chip’s stabilizing capabilities, while at least eight peer-reviewed studies and 25 clinical and scientific reports also validated the technology. Backed by such an impressive body of scientific research that supports the company’s technology, it’s no surprise that the company has been growing its topline at a healthy clip. Revenue growth has been robust, and over the past two years alone, the company has doubled its revenue consistently. According to the company’s most recent earnings results, Aires brought in $5.5 million in revenue for the first 9 months of 2022, representing a 63% YoY increase. Extrapolating this growth rate over the whole of 2023, Airestech could be sitting on $10 million in 2023 sales. What's even more appealing about American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) is that it boasts superior profit margins. At the moment, its gross margins average about 60%, illustrating just how lucrative the opportunity in this space is. This level of profitability essentially puts Aires right up there with the top technology companies like Nvidia and Apple, which had 75% and 45% gross margins, respectively. The company also reached a key milestone after achieving positive EBITDA (adjusted) in its most recent quarter. A multi-billion-dollar market As you have probably realized by now, it is practically impossible to avoid EMF radiation in our technology-reliant world. That is why investors are taking a close look at American Aires Inc., which seems well positioned to capitalize on this huge opportunity. The market for Aires products is applicable to diverse customer segments, including biohackers, tech-savvy athletes, individuals focused on fertility, those seeking better sleep, and most recently, gamers. The U.S. market alone could be potentially worth $5 billion, which is just a tiny fraction of the global opportunity. Currently, American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) operates an online direct-to-consumer sales model with fulfillment centers in the USA, Canada, Australia, and the EU and a customer base of 54,000 clients spread out across 65 countries. However, the company believes that it has the opportunity to further expand its reach now that its products have been especially popular among high-performing athletes and celebrities who value health and wellness. That explains why earlier this month Aires announced the launch of its new campaign, #airesathletes, to broaden its impact within the elite performance sphere, with UFC star Maycee Barber as the first athlete partner. Maycee "The Future" Barber is a formidable presence in the women's flyweight division of the Ultimate Fighting Championship (UFC). Last year, the UFC and WWE merged to form TKO Group (NYSE:TKO), and Aires’ initiative aims to connect with professional athletes who have turned to the company for the significant benefits its technology offers, particularly in terms of physiological optimization through EMF modulation as well as the proven protection from external EMF sources. And just earlier this week, American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) announced that it had signed another strategic partnership with William Morris Endeavor Entertainment (WME), a titan in entertainment, sports, and fashion. WME is a leader in the global entertainment arena, bringing to the table a vast network of world-class artists, athletes, and content creators and a proven track record in talent management and strategic marketing. That means WME is perfectly positioned to elevate Aires' footprint, increasing brand reach and engagement and underscoring the extensive benefits of Aires' solutions for wellness and performance optimization. WME is part of Endeavor Group Holdings, Inc. (NYSE:EDR), a global sports and entertainment behemoth that has a 51% stake in TKO. This collaboration will harness the growing interest from elite athletes and performers in Aires' innovative solutions and capitalize on the momentum Aires has built among top-tier athletes, expanding on the recently launched #airesathlete campaign. Additionally, this partnership between American Aires and WME underscores a transformative vision: Aires Technology, already trusted by elite athletes and performers for its unmatched performance and recovery benefits, is poised to become a global standard for EMF protection and physiological optimization. CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by a third party to assist in the production and distribution of content related to American Aires Inc.. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details CapitalGainsReport Mark McKelvie +1 585-301-7700 Markrmckelvie@gmail.com Company Website http://CapitalGainsReport.com

March 20, 2024 05:00 AM Eastern Daylight Time

IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

IGC Pharma, Inc. (IGC)

By Faith Ashmore, Benzinga Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact of Alzheimer’s disease makes it a major healthcare challenge. In 2023, Alzheimer’s and other types of dementia were projected to cost the U.S. $345 billion. By 2050, these costs could rise to nearly $1 trillion. While no cure currently exists for Alzheimer's, promising advancements in research and treatment are bringing hope to patients and their families. Hope On The Horizon? IGC Pharma (AMEX: IGC) is one of the companies hoping to provide solutions for millions of suffering Americans. It is a pharmaceutical company focused on developing innovative therapies for various medical conditions and fields, including Alzheimer's disease, chronic pain and women’s health. The company specializes in advanced formulas and the company’s lead drug candidate is IGC-AD1. IGC-AD1 is undergoing extensive clinical trials to evaluate its effectiveness and safety in treating Alzheimer's disease. The phase two clinical trial, initiated in 2023, encompasses 20 sites across the United States and Canada. With a target of 146 participants, this trial focuses on determining the efficacy of IGC-AD1 in alleviating agitation, a common symptom experienced by many Alzheimer's patients. IGC-AD1 has patent protection for its unique formulation, which involves a combination of two Active Pharmaceutical Ingredients (APIs). This combination is administered as an oral liquid solution, making it more accessible and convenient for patients. Pre-clinical studies of IGC-AD1 have demonstrated its potential in reducing the production of Aβ40 peptide and inhibiting the aggregation of Aβ42, both of which are associated with Alzheimer's. During phase one trials, patients with mild to severe Alzheimer's disease participated in a double-blind trial, where IGC-AD1 was administered at three different doses over a period of 14 days. The results were encouraging, as IGC-AD1 proved to be safe and well-tolerated by the participants, with no significant adverse effects reported. The study also demonstrated improvements in Neuropsychiatric Symptoms (NPS), specifically in the domains of agitation, anxiety and depression. These positive changes also led to a reduction in caregiver distress. With the success of phase one trials, the company expects the phase two clinical trial to provide further insights into the efficacy and safety of IGC-AD1. As researchers and healthcare professionals continue to investigate this potential treatment, IGC-AD1 could bring hope to the millions of individuals living with Alzheimer's disease and their loved ones. IGC Pharma also has four other drugs in the pipeline that are at the pre-clinal stage. TGR-63 targets early-moderate-stage Alzheimers and so far, has been shown to improve memory and learning in mice models at the pre-clinical stage. The other drugs in the company’s pipeline are 1C, M3, and LMP, and it also has a variety of patents that focus on a wide range of targets, from eating disorders to epilepsy and more. Featured photo by bruce mars on Unsplash IGC Pharma Inc. (IGC) is at the forefront of the fight against Alzheimer's disease, developing innovative solutions to address this devastating illness. The company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2b clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer's. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma is actively leveraging Artificial Intelligence (AI) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission ("SEC") filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Rosalyn Christian rchristian@imsinvestorrelations.com Company Website https://igcpharma.com/

March 19, 2024 04:00 PM Eastern Daylight Time

Image

1 ... 47 48 49 50 51 ... 310